TAKE Solutions Certified as Generis’ Platinum Implementation Partner for CARA User Interface to Documentum

TAKE Life Sciences has become the first Generis Platinum Implementation Partner for Generis’ CARA product, the market-leading user interface software for Documentum.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
TAKE Solutions is extremely pleased to partner with Generis on the CARA product, which is a fast, user-friendly, configurable User Interface that has been proven with a range of Pharma and Biotech businesses.- Jim Tizzard, CEO of TAKE Life Sciences

Chennai, India (PRWEB) June 11, 2014

TAKE Solutions Ltd. (BSE: 532890), TAKE Life Sciences has become the first Generis Platinum Implementation Partner for Generis’ CARA product, the market-leading user interface software for Documentum. The Platinum Partner level at Generis signifies that TAKE has certified a minimum of 20 staff on CARA and been engaged in a minimum of 3 implementation projects.

The strategic partnership will enable Generis and TAKE Solutions offer customers a proven, cost-effective and highly flexible user interface option, when they consider how to upgrade from Webtop. CARA not only provides a high degree of ergonomic and functional advantages, but comes with a set of Life Sciences solutions pre-packaged as accelerators or “RapidDeploy” options, including Submission/CTD, Electronic Trial Master File (eTMF), SOPs/Quality Management, and Change Control. TAKE Solutions has senior Content Management consultants who have successfully completed the CARA training and certification program, which qualifies these individuals as experts. This will benefit Generis and TAKE customers tremendously in the implementation and support for CARA.

"Our partnership with TAKE Solutions enables us to offer our CARA user interface product backed by the domain expertise of the implementation teams from TAKE Solutions. By becoming our first Platinum Implementation Partner, TAKE Solutions has demonstrated their commitment to providing our customers with best of breed project support and delivery capabilities,” said James Kelleher, Chief Executive Officer, Generis

Jim Tizzard, CEO, TAKE Life Sciences said,"TAKE Solutions is extremely pleased to partner with Generis on the CARA product, which is a fast, user-friendly, configurable User Interface that has been proven with a range of Pharma and Biotech businesses. We continue to expand our relationship with the leading Document UI vendor and we are confident our partnership will ensure clients’ needs are well understood and effectively addressed“.

About TAKE Solutions Inc.
TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE] TAKE Life Sciences provides consulting, technology and functional services across Clinical, Regulatory and Safety by leveraging its deep domain knowledge and technical expertise.

With a team of over 500 Life Science professionals in Europe, North America and India, TAKE Life Sciences has over 18 years’ experience working in the Safety, Regulatory, Quality and Compliance areas. TAKE supports clients in the North America, Europe, MENA and APAC.

TAKE has a proven track record as a trusted partner in delivering world-class solutions to more than 400 customers worldwide. For more information, please visit http://www.takesolutions.com.

About Generis Knowledge Management, Inc.
Generis has been providing leading-edge software for content management systems including Documentum, SharePoint, Alfresco and Oracle WebCenter since 1997. The company has more than 40 customers across industries from Federal Government, through Life Sciences and Engineering to Media, Publishing and Financial. The company is headquartered in Princeton, NJ, and has its principal development centers in Poland and Ukraine.

In addition to the market-leading CARA user interface, which CMSwire called “a pretty slick tool”, Generis also provides a number of add-on modules to handle watermarking, eSignature, data migration and import / export, annotations, hyperlinking and publishing. For more information about Generis, visit http://www.generiscorp.com.


Contact